Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A3 | P38919 | 1/20 | 0.61 |
| ▸ | GPR17 | Q13304 | 4/20 | 0.58 |
| ▸ | PRNP | P04156 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29062814 | 0.85 | GPR17 (0.47) | EIF4A3GPR17PRNPCYP1A2CYP2C9 | |
| SCHEMBL2490053 | 0.83 | EIF4A3 (0.65) | EIF4A3GPR17CYP2C19GPR35MEN1 | |
| SCHEMBL20534662 | 0.81 | EIF4A3 (0.46) | EIF4A3GPR17PRNPCYP1A2CYP2C9 | |
| SCHEMBL24113129 | 0.81 | MAPT (0.48) | EIF4A3GPR17CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8793810 | 0.81 | GPR17 (0.60) | EIF4A3GPR17PRNPCYP1A2CYP2C9 | |
| SCHEMBL21341417 | 0.80 | GPR17 (0.58) | GPR17PRNPCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11995204 | 0.80 | EIF4A3 (0.66) | EIF4A3MEN1KMT2A | |
| SCHEMBL20535547 | 0.78 | ALOX15 (0.50) | GPR17NPSR1 | |
| SCHEMBL25758846 | 0.78 | EIF4A3 (0.49) | EIF4A3GPR17CYP1A2CYP2C19NPSR1 | |
| SCHEMBL20494364 | 0.78 | GPR17 (0.65) | EIF4A3GPR17GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250243202-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-31 | — | — | US | disclosed |
| CN-115785100-B | Compounds useful as RET inhibitors | 癌症研究科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240132504-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-04-25 | — | — | US | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-4105219-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS RET INHIBITORS | Cancer Research Technology Limited (GB) | 2022-12-21 | — | — | EP | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220348585-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-11-03 | — | — | US | disclosed |
| CN-110506043-B | Compounds useful as RET inhibitors | 癌症研究科技有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-11352361-B2 | Compounds useful as RET inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| EP-3609898-B1 | COMPOUNDS USEFUL AS RET INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2022-06-01 | — | — | EP | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200157107-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-21 | — | — | US | disclosed |
| EP-3609898-A1 | COMPOUNDS USEFUL AS RET INHIBITORS | Cancer Research Technology Limited (GB) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018189553-A1 | COMPOUNDS USEFUL AS RET INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | EIF4A3 566/4885GPR17 4635/4885PRNP 241/4885 |
| US-20250243202-A1 | Compounds Useful as RET Inhibitors | RET, BCR, REL | EIF4A3 1354/4885GPR17 3102/4885PRNP 2426/4885 |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | EIF4A3 608/4885GPR17 4101/4885PRNP 93/4885 |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | EIF4A3 608/4885GPR17 4101/4885PRNP 93/4885 |
| US-20220348585-A1 | Compounds Useful as RET Inhibitors | RET, BCR, REL | EIF4A3 1354/4885GPR17 3102/4885PRNP 2426/4885 |
| US-11352361-B2 | Compounds useful as RET inhibitors | RET, BCR, REL | EIF4A3 1354/4885GPR17 3102/4885PRNP 2426/4885 |
| US-20200157107-A1 | Compounds Useful as RET Inhibitors | RET, BCR, REL | EIF4A3 1354/4885GPR17 3102/4885PRNP 2426/4885 |
| US-20240132504-A1 | Compounds Useful as RET Inhibitors | RET, BCR, REL | EIF4A3 1354/4885GPR17 3102/4885PRNP 2426/4885 |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | EIF4A3 608/4885GPR17 4101/4885PRNP 93/4885 |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | EIF4A3 608/4885GPR17 4101/4885PRNP 93/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | EIF4A3 582/4885GPR17 4178/4885PRNP 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.